Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-015787

CHIEF SCIENTIFIC OFFICER sold 7,500 shares at $20.03 ($150,220)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2025-06-03 Sale : show line 1 in the form 10b5-1 −7,500 $20.03 $150,220 977,688 I
Open-market sales · 7,500 sh · avg $20.03 · $150,220
Loading xslF345X05/form4-06052025_080654.xml…